Reuters logo
2 个月内
BRIEF-Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083
2017年5月11日 / 下午12点58分 / 2 个月内

BRIEF-Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083

1 分钟阅读

May 11 (Reuters) - Delmar Pharmaceuticals Inc:

* Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083 in recurrent glioblastoma multiforme (gbm)

* Delmar Pharmaceuticals- have resources to initiate phase 3 study of val-083 as single agent treatment for gbm patients who failed both temozolomide & bevacizumab Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below